Invasive fungal infections in Neonatal Intensive Care Units of Southern Italy: a multicentre regional active surveillance (AURORA Project) by Montagna, Maria Teresa et al.
125
J prev med hyg 2010; 51: 125-130
Introduction 
During the past two decades invasive fungal infections 
(IFIs) have become an increasingly important problem 
in preterm infants hospitalized in the Neonatal Intensive 
Care Unit (NICU). Candida spp is the third most-com-
mon agent of late-onset infections in critically ill ne-
onates, especially in very low birth weight (1001-1500 g, 
VLBW) and extremely low birth weight (≤ 1000 g, 
ELBW) infants [1, 2], with an incidence ranging from 
2.6 to 10% among VLBW [3-5], and from 5.5 to 20% 
among ELBW [2, 6, 7]. 
Although C.albicans is the most frequent aetiological 
agent, infections due to C. non-albicans have increased 
in frequency in recent years [8-10]. In many NICUs 
C.parapsilosis is the main pathogen causing clusters and 
nosocomial outbreaks [11-13]. Numerous risk factors for 
invasive candidiasis (IC) have been identified in NICU 
patients: some are related to host factors (immunodefi-
ciency resulting from decreased numbers of neutrophils 
and T cells, immature skin structure, Candida coloniza-
tion), others to medical care (central venous catheters, 
total parenteral nutrition, mechanical ventilation, broad 
spectrum antibiotic therapy, use of 3rd generation ce-
phalosporin, administration of H2-blockers) [7, 14-17]. 
The mortality rate is high (25-60%) [17] and it is relat-
ed to the difficulty to make an early diagnosis because 
of reduced sensitivity of diagnostic tests, non-specific 
clinical signs and to inadequate and / or delayed treat-
ments [18, 19].
The present paper originates from the results of an ac-
tive surveillance of IFIs carried out in the Southern Italy 
(Apulia region) throughout a 18-month period, focusing 
on the characteristics of neonatal IFIs, as incidence, ae-
tiology and resistance to common antifungal drugs, and 
on the role of the additional biomarker-diagnostic test. 
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Summary
Introduction. During the past years invasive fungal infections 
(IFIs) have become an increasingly important problem in infants 
hospitalized in the Neonatal Intensive Care Unit (NICU). Candida 
species is the third most-common agent of late-onset infections in 
critically ill neonates, with an estimated incidence of 2.6-10% in 
very low birth weight and 5.5-20% in extremely low birth weight 
infants. 
The aim of this observational study is to evaluate the epidemiol-
ogy of IFIs among infants admitted to NICUs of one Italian region 
by a multicenter surveillance (Aurora Project).
Methods. The IFIs surveillance was carried out prospectively in 
Apulia (Southern Italy) between February 2007 and August 2008. 
This report focuses on the results from 6 enrolled NICUs.
Results. Twenty-one neonates developed IFIs: the overall inci-
dence was 1.3% and crude mortality was 23.8%. Infants weigh-
ing ≤ 1500g (4.3%) showed a significantly higher incidence 
than those ≥ 2500g (0.2%). C.parapsilosis (61.9%) was the 
most frequent isolated species. The main potential risk factors 
were having a central venous catheter placed, length of stay 
in NICU > 7 days and total parenteral nutrition for > 5 days. 
The (1,3)-ß-D glucan (BDG), mannan antigens and anti-Can-
dida antibodies’ evaluation was performed in 7 neonates. All 
neonates were positive to the BDG; the mannan antigen result 
was positive in 5 newborns, the anti-mannan antibodies were 
always negative. All isolates were amphotericin B and flucona-
zole-susceptible. 
Discussion. This first prospective study on neonatal fungal infec-
tion in one Italian region gives evidence of a preponderance of 
non-albicans Candida spp and indicates potential utility of BDG 
as an adjunct diagnostic test. 
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Methods
Study design
A prospective multicenter surveillance (Aurora Project) 
was carried out in Apulia for a 18 month period (Febru-
ary 2007 - August 2008). The Apulia region is located 
in Southern Italy, has about 4 million inhabitants, with 
38,000 births/year and a mean of 850,000 hospital ad-
missions/year. The aim of this surveillance was to verify 
the incidence of IFIs among patients admitted to general 
ICUs, haematology wards and NICUs of this region, 
together with the causative pathogens, potential predis-
posing factors, treatment characteristics, as well as to 
determine the antifungal susceptibility patterns of the 
isolated yeasts. In this present paper, we report the data 
concerning the neonatal subjects.
All six participating NICUs followed the Italian Society 
of Neonatology’s guidelines and recommendations pro-
moting the use of breast milk, both expressed or banked, 
in VLBW neonates, as well as written common policies 
concerning the use of antibiotics and probiotics. 
According to the protocol, for each IFIs episode par-
ticipating hospitals had to identify and store the fungal 
isolates and to complete an electronic report form about 
clinical data (age, sex, birth weight, underlying disease), 
microbiological diagnosis (techniques used to isolate 
and identify the etiological agents, valuation of circulat-
ing antigens and antibodies), risk or predisposing factors 
(vascular lines, total parenteral nutrition, endotracheal 
intubation, previous Candida colonization), therapeutic 
approach and outcome 30 days after diagnosis. 
All reports and isolates were sent to the Coordinating 
Center (CC, Laboratory of Mycology - Department of 
Biomedical Sciences and Human Oncology, University 
of Bari “Aldo Moro”) for data analysis, species confir-
mation and antifungal susceptibility testing. 
Case definitions and inclusion criteria
IFI cases were defined using the criteria of the inter-
national guidelines [20, 21] and the recommendations 
of the Italian Neonatology Society’s Fungal Infections 
Task Force [22]. 
A microbiologically documented fungal infection was 
defined through a positive culture from sterile sites 
(blood, cerebrospinal fluid and urine collected by su-
prapubic sterile puncture or sterile bladder catheteriza-
tion, with growth of > 10 000 CFU/mL) of an infant with 
clinical signs of infection (apnea, elevated or depressed 
leukocyte count, increased C-reactive protein levels, ab-
dominal distension, thrombocytopenia). 
An episode of IFI was considered new infection in the 
same infant if it occurred at least 15 days after the first 
isolation. 
Candidemia was defined as blood culture drawn from 
either an intravascular catheter or a peripheral vein, 
positive for Candida spp. Duration of candidemia was 
defined by the number of days between the first and the 
last blood cultures yielding the same Candida species. 
Persistent candidemia was defined as the isolation of the 
same Candida species from blood cultures for at least 5 
consecutive days despite therapy. Disseminated infec-
tion was defined as positive cultures from more than one 
normally sterile body fluid or site.
In the present study, all possible fungal infections cases 
and superficial mycoses were excluded from the analy-
sis.
Laboratory procedures
Detection and determination of different isolates were 
performed by each laboratory according to their stand-
ard protocols. The CC sub-cultured all the isolates on 
antimicrobial agent-free Sabouraud dextrose agar plates 
(bioMérieux, Marcy l’Etoile-France) and CHROMagar 
Candida Medium (Becton Dickinson, Germany) to en-
sure viability and purity. The yeasts identification was 
confirmed by germ tube production and sugar assimila-
tion profiles obtained using the API ID32C and VITEK 
System (bioMérieux, Marcy l’Etoile-France). Differen-
tiation of the two closely related species Candida albi-
cans and Candida dubliniensis was made by different 
carbohydrate assimilation and ability to grow at 45°C. 
Mannan antigen was measured using a commercial 
sandwich immunoassay, Platelia Candida Ag (BioRad, 
Marnes La Coquette, France), while anti-mannan an-
tibodies were assessed using a two-stage indirect im-
munoassay, Platelia Candida Ab/Ac/Ak kit, (Bio-Rad, 
Marnes La Coquette, France). Both tests were performed 
according to the instructions of the manufacturer. The 
presence of (1,3)-ß-D-glucan (BDG) was measured by 
a colorimetric assay, Fungitell (Associates of Cape Cod 
Inc., E. Falmouth, MA, USA). 
The in vitro antifungal susceptibility test was performed 
using the broth microdilution method in accordance 
with the CLSI M27-A3 recommendations [23]. The 
antifungal drugs tested were amphotericin B (AmB), 
anidulafungin (AND), caspofungin (CS), fluconazole 
(FL), itraconazole (IT), voriconazole (VO), posacona-
zole (POS). CLSI breakpoints for susceptibility were 
used for AND, CS, FL, VO, while a provisional sus-
ceptibility breakpoint of ≤ 1 µg/ml was used for AmB 
and POS [24]. C.krusei ATCC 6258 and C.parapsilosis 
ATCC 22019 were used as control strains in all tests. 
Statistical Analysis
Data were entered into a database (Microsoft Access 
2003). Statistical analysis was performed with the free 
software R (version 2.10.0). Categorical variables are 
expressed as proportions or percentages, and numerical 
data are expressed as the median ± SD and range.
Results
During the 18-month study period, 1597 infants were ad-
mitted to the 6 participating NICUs, of whom 248 were 
VLBW and 171 ELBW. Among all enrolled infants, 21 
developed IFIs with an overall incidence of 1.3% (Tab. 
I). The incidence of IFIs was inversely proportional 
to birth weight: 4.7%, 4% and 0.2% of infants weigh-
ing ≤ 1000, ≤ 1500, ≤ 2500 g respectively. 
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Bloodstream infection was the most frequent IFI (95.2%): 
12 episodes were caused by C.parapsilosis (60%), 7 by 
C.albicans (35%) and 1 by C.glabrata (5%). Moreover, 
1 C.parapsilosis disseminated infection was diagnosed 
(4.8%). 
The demographic characteristics and underlying diseases 
are shown in Table II. The overall male/female ratio was 
12/9. The median age at diagnosis was 39.7 ± 40.6 days 
(range, 5-150) and 2 (9.5%) neonates were ≤ 7 days old 
when IFI occurred. Ten neonates (47.6%) were VLBW, 
8 (38.1%) ELBW and only 3 (14.3%) infants were low 
birth weight (1501-2500g). The most common underly-
ing disease was respiratory distress syndrome (57.1%). 
The presence of a central venous catheter in situ for > 4 
days was the most frequent predisposing factor for IFI 
(100%), followed by a length of stay > 7 days (90.5%), 
receiving total parenteral nutrition for > 5 days (90.5%), 
a birth weight ≤ 1500 g (85.7%), gestational age < 32 
weeks (71.4%), mechanical ventilation (61.9%), previous 
Candida spp colonization in more than two sites (47.6%), 
multiple antibiotic therapy ≥ 5 days (47.6%) (Tab. III). 
The Central Venous Catheter (CVC) was removed in 20 
episodes (95.2%): in 7 patients (35%) at the time of blood 
sampling, in 13 (65%) 5.1 ± 4.9 days (range, 1-20) after 
the onset of candidemia. In 19 (95%) cases, catheter tip 
culture was performed, of which 17 (89.5%) were posi-
tive for the same fungal species found in blood culture. 
The mean duration of IC was 3.5 ± 5.1 days (range 1-20). 
Persistent candidemia was found in 5 (23.8%) neonates 
(range, 5-20 days). Mixed infections were documented 
in 2 (9.5%) infants: C.parapsilosis associated with Pseu-
domonas aeruginosa and C.parapsilosis associated with 
Chryseobacterium meningosepticum. 
The BDG, mannan antigens and anti-mannan antibodies 
detection was performed in only 7 babies suspected to 
have candidiasis. All neonates were positive according to 
the BDG test (> 80 pg/ml). The mannan antigen resulted 
positive in 5 newborns (> 0.5 ng/ml) while the anti-man-
nan antibodies were always negative (< 5 UA/ml). 
Before candidemia was detected, one preterm birth (< 24 
weeks) had received antifungal prophylaxis with FL (3 
Tab. I. IfI incidence in 6 NICUs included in the surveillance.
NICUs No. of beds No. admitted No. (%) IFIs Incidence/100 admitted
a   6 240 7 (33.4) 2.9
B 10 220 4 (19.0) 1.8
C   8 280 3 (14.3) 1.1
d   8 331 3 (14.3) 0.9
e   4 259 2 (  9.5) 0.8
f   8 267 2 (  9.5) 0.7
Total 44        1597  21 (100) 1.3
Tab. II. demographic characteristics and underlying diseases of 21 
screened patients.
Characteristic
   Patient
 No.   %
Sex
   male 12 57.1
   female   9 42.9
Age (days) - mean ± SD 39.7 ± 40.6                     
[range 5-150]
Birth weight (g)
   ≤ 1000 (elBW)   8 38.1
   1001-1500  (vlBW) 10 47.6
   1501-2500 (lBW)   3 14.3
Underlying disease
   respiratory distress syndrome 12 57.1
   Necrotizing enterocolitis   3 14.3
   Short bowel syndrome   2   9.5
   esophagel atresia   1   4.8
   ectodermal dysplasia   1   4.8
   Bronchopulmonary dysplasia   1   4.8
   Cerebral hemorrhage   1   4.8
Tab. III. potential predisposing factors of 21 IfI cases by Candida albicans or non albicans Candida spp. 
Predisposing factors
           All Candida spp  
        (n = 21)
C. albicans
(n = 7)
         C. non-albicans      
    (n = 14)
Central venous catheter 21 (100)* 7 (100) 14 (100)
length of stay >7 days 19 (90.5) 6 (85.7)      13 (92.8)
total parenteral nutrition 19 (90.5) 5 (71.4)     14 (100)
Birth weight ≤1500 g 18 (85.7) 5 (71.4)      13 (92.8)
gestational age < 32 weeks 15 (71.4) 6 (85.7)       9 (64.3)
mechanical ventilation 13 (61.9) 5 (71.4)       8 (57.1)
Candida colonization 10 (47.6) 5 (71.4)       5 (35.7)
antibiotic therapy 10 (47.6) 3 (42.8)       7 (50.0)
previous surgery 1 (4.8) –        1 (7.1)
*Numbers in parentheses, percent
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mg/kg/day) and 6 (28.6%) an empirical treatment with 
FL (6 mg/kg/day). 
After diagnosis, all the patients received antifungal ther-
apy: 15 (71.4%) were treated with liposomal AmB (1-5 
mg/kg/day), 5 (23.8%) with FL (6 mg/kg/day). Only in 
one case (4.8%) FL therapy for 4 days (6 mg/kg/day) 
was later switched to liposomal AmB (3 mg/kg/day) be-
cause of clinical complications. Median length of treat-
ment was 17 days (range, 7-38 days). 
Overall mortality was 23.8%: 4 patients died by 
C.parapsilosis and 1 by C.glabrata. Death occurred after 
11 ± 4.1 days (range, 7-16) from the onset of infection; it 
was observed in newborns with a birth weight ≤ 1500 g 
and a gestional age < 32 weeks.
Antifungal susceptibility tests were carried out on all 21 
Candida spp isolates (Tab. IV). All yeasts were suscep-
tible to tested antifungal drugs, except 4 C.parapsilosis 
that resulted resistant to IT (MIC 1 µg/ml) and 1 
C.glabrata that was dose-dependent susceptible to FL 
(MIC 16 µg/ml) and resistant to IT (MIC 4 µg/ml).
Discussion
To our knowledge, this is the first prospective multicent-
er survey presenting epidemiological data on neonatal 
IFIs from one Italian region. In fact several studies car-
ried out in Italy are reviews of an individual hospital or 
regard specific patients population [25-28]. 
Consistent with earlier reports in the literature [5, 8, 29], the 
overall incidence is 1.3%, with an incidence significantly 
higher in neonates weighing ≤ 1500g (4.3%, 18/419) than 
in those ≥ 2500g (0.2%, 3/1178) (p < 0.001).
In our study, a variety of predisposing factors were iden-
tified. They are largely similar to those reported in pre-
vious studies [14-17], but it is difficult to assess to what 
these factors contributed to development of IFIs, because 
this survey was not carried out on a control population 
(no infected with fungi).
All infants had an intravascular catheter that was re-
moved in 95.2% of the episodes: 89.5% of evaluated 
catheters were positive for same Candida species iso-
lated from the blood, highlighting the catheter as pos-
sible source of candidemia. C.parapsilosis was isolated 
more frequently than C.albicans (61.9% vs 33.3%). The 
high incidence of C.parapsilosis infections may be cor-
related to its ability to form biofilms on catheters and to 
contaminate glucose-containing solutions (e.g. parenter-
al nutrition) [4, 30]. However, a possible transmission 
of C.parapsilosis from hands of healthcare workers to 
neonates has been suggested in cases of infection CVC-
related, because it is a commensal of human skin (hori-
zontal transmission) [4, 9, 11, 30, 31].
A previous colonization by Candida spp was demon-
strated in 47.6% of episodes, mainly in urinary (100%), 
respiratory (87.5%) and intestinal (50%) system. Fun-
gal colonization is very common among NICU patients 
not receiving antifungal prophylaxis [17]. Manzoni et 
al. [15, 32] showed that Candida colonization in multi-
ple body sites is an important predictor of progression 
to IFI, underlining the need of systematic surveillance 
cultures in the preterm infants. 
The search for mannan antigen by ELISA has good spe-
cificity for the diagnosis of IC in severely ill patients, 
although this technique requires frequent sampling due 
to the rapid clearance of this antigen from the blood. 
Recent studies have demonstrated a good diagnostic ef-
ficacy with the association of anti-mannan antibodies, 
but not in immunocompromised patients [33, 34]. Oliv-
eri et al. [35] demonstrated that the sensitivity and spe-
cificity of mannan antigen test for IC in NICUs were 
94.4% and 94.2% respectively, with a positive predic-
tive value of 85% and a negative predictive value of 
98%. Besides, during last years, the BDG detection as 
bio-markers fungus-specific seems to give a new di-
agnostic approach with encouraging results especially 
if it is valuated in tandem of mannan and anti-mannan 
antibodies, but its diagnostic performance is not well 
characterized [36, 37]. In our study, because of babies 
critical conditions, the mannan and BDG antigens de-
tection was performed in only 7 infants: the mannan 
antigen resulted positive in 5 cases (4 with C.albicans 
and 1 with C.glabrata infection), and negative in 2 
patients with C.parapsilosis infection, while BDG re-
search was always positive. The low sensitivity of the 
mannan antigen test in patients with C.parapsilosis in-
vasive infection is in agreement with what suggested 
by other Authors [35, 38]. Although our data refer a 
limited number of patients, we believe that the circu-
lating antigens monitoring in NICU patients may be an 
useful contribution to the diagnosis of IC. In fact, the 
detection of BDG and mannan antigens, such as anti-
Tab. IV.  In vitro antifungal susceptibilities (µg/ml) of 21 Candida spp isolates (ClSI test).
Drugs
C. albicans
(n = 7)
C. parapsilosis
(n = 13)
C. glabrata
(n = 1)
MIC90 Range MIC90 Range  MIC
anidulafungin 0.25 0.016-0.25 2 1-2 0.125
Caspofungin 1 0.06-1 2 2 2
posaconazole 0.06 0.008-0.06 0.125 0.016-0.25 1
voriconazole 0.008 0.008-0.016 0.03 0.008-0.03 1
Itraconazole 0.25 0.016-0.5 1 0.06-1 4
fluconazole 0.25 0.125-0.25 2 0.25-8 16
amphotericin B 0.5 0.125-0.5 1 0.06-1 1
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mannan antibodies finding, singly or in combination, 
could improve the sensitivity and help eliminating false 
positive or negative results.
All our C.albicans strains were susceptible to the an-
tifungal tested drugs. Similarly, C.parapsilosis isolates 
were susceptible, except 4 strains (30.8%) resistant 
to IT (MIC 1 µg/ml); the only C.glabrata strain was 
dose-dependent susceptible to FL (MIC 16 µg/ml) and 
resistant to IT (MIC 4 µg/ml). According to other Au-
thors [8, 9], we have not found any significant resistance 
to AmB and FL, which are the antifungal drugs used for 
prophylaxis and treatment of IC in neonates [21]. The 
very low rate of azole resistance may be related to the 
treatment policy in use at our region: systemic antifun-
gal prophylaxis and/or empiric therapy with FL were 
not usually employed; in fact their use was restricted 
only to few infants (1 and 6 respectively) in our study. 
We think the FL use as prophylaxis or starting therapy 
should be evaluated according to the epidemiology of 
the local NICU: if the incidence is low, it could be a bet-
ter approach to use, as prophylaxis, probiotics [39] or 
lactoferrin [40] and save FL to treat documented infec-
tions. However, it is important to monitor susceptibil-
ity pattern of clinical isolates, particularly non-albicans 
Candida ones, to identify strains resistant to common 
antifungal drugs [41]. 
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